Trial Profile
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Celecoxib (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Estradiol (Primary) ; Metformin (Primary) ; Zoledronic acid (Primary) ; Antiandrogens; Apalutamide; Degarelix; Goserelin; Leuprorelin; Prednisolone; Prednisone; Triptorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms STAMPEDE
- 01 Jan 2024 Results from NCT00303784 and NCT00268476 assessing androgen suppression, quality of life and bone health indices and cardiovascular events , published in the Clinical Oncology
- 24 Oct 2023 Results (n=1791) assessing long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer with follow-up to Mar 2021 for patients randomised 1:1 in England between arms A (standard of care [SOC]) and H (SOC+RT) presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.